Advertisement

Probleme und Prinzipien der Hormontherapie des fortgeschrittenen Prostatakarzinoms

  • J. E. Altwein
  • P. Faul

Zusammenfassung

In einer Vielzahl von Experimenten wurde gezeigt, daß Androgene die Synthese der DNS in den normalen und maligne entarteten Zellen der Prostata stimulieren (Farnsworth 1970; Lesser u. Bruchovsky 1973; Mc Mahon et al. 1972; Sufrin u. Coffey 1973). Da Hormone mit androgener Wirkung über diesen Mechanismus auch die Zeilproliferation stimulieren, war die Androgendeprivation ein möglicher Weg zur Behandlung des Prostatakarzinoms, der seit 50 Jahren praktiziert wird (Huggins u. Hodges 1941; Klosterhalfen u. Becker 1987; Paulson 1985; Smith 1987). Die Entwicklung und der klinische Einsatz von nebenwirkungsarmen LH RH-Analoghormonen und Antiandrogenen wir Cyproteronazetat1, Flutamid2, Nilutamid3 und ICI 176 3343a, bedingten einen Wandel der hormonalen Androgendeprivation. Dies hatte zur Folge, daß die mit erheblichen Nebenwirkungen belastete Gabe von Östrogenen von einzelnen Autoren bereits als obsolet gesehen wird (86).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Ahmed SR, Grant JPF, Shalet SM (1985) Preliminary report on use of depot formulation of LH RH analogue ICI 118630 (Zoladex) in patients with prostatic cancer. Clin Res 290: 185–187Google Scholar
  2. Altwein JE (1979) Hormontherapie des Prostatakarzinoms. Beitr Onkol 1: 78–90Google Scholar
  3. Altwein JE (1983) Estrogens in the treatment of prostatic cancer. In: Pavone-Macaluso M, Smith P (eds). Cancer of the prostate and kidney. Plenum, New York, pp 317–32Google Scholar
  4. Altwein JE, Leitenberger A, Ay R (1984) Wert der Computertomographie und Lymphographie zum Nachweis von pelvinen Lymphknotenmetastasen beim Prostatakarzinom. Urol Int 39: 178–183PubMedCrossRefGoogle Scholar
  5. Altwein JE (1986) Wertung der Hormontherapie des metastasierenden Prostatakarzinoms. Onkol Forum Chemother 2: 1–9Google Scholar
  6. Andersson L, Edsmyr F, Könyves I (1983) Estramustine and predimustine. In: Pavone-Macaluso M, Smith P (eds) Cancer of the Prostate and Kidney, PlenumGoogle Scholar
  7. Aulitzky W, Frick J (1988) Unterschiedliche Effekte von LH RH-Analoga auf die Testosteron-Sekretion während der Initialphase der kombinierten antiandrogenen Therapie beim Prostatakarzinom. In: Die Prostata; Bd. 4. PMI, Frankfurt, S 218-224Google Scholar
  8. Beach PD (1979) Hormonal therapy for prostatic carcinoma. In: Johnson DE, Samuels ML (eds) Cancer of the genitourinary tract, Raven, New York, pp 273–278Google Scholar
  9. Berry WR, Larzlo J, Cox E (1979) Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate. Cancer 44: 763–775PubMedCrossRefGoogle Scholar
  10. Bertagna C, Fiet J, de Gery A, Hucher M (1987) Endocrine effects of the pure antiandrogen Anandron in castrated patients with metastatic prostatic cancer. Eur J Cancer Clin Oncol 23: 1233CrossRefGoogle Scholar
  11. Blackard CE, Byar DP, Jordan WP (1973) Orchiectomy for advanced prostatic carcinoma. Urology 1: 553–560PubMedCrossRefGoogle Scholar
  12. Borgmann V, Nagel R, Schmidt-Gollwitzer M (1982) Langzeitsuppression der gonadalen Testosteronproduktion durch den LH RH-Agonisten (Buserelinacetat; Hoe 766) beim fortgeschrittenen Prostatakarzinom eine neue Therapieform? Akt Urol 13: 200–203CrossRefGoogle Scholar
  13. Bouffioux C (1979) Le cancer de la prostate. Acta Urol Belg 47: 189–470PubMedGoogle Scholar
  14. Bruchovsky N (1980) Molecular action of androgens and antiandrogens. In: Hammerstein J, Lachnit Fixon U, Neumann F et al (eds) Androgenization in Women. Excerpta Medica, Amsterdam, pp 7–20Google Scholar
  15. Byar DP (1973) The VACURG’s studies of cancer of the prostate. Cancer 32: 1126–1130PubMedCrossRefGoogle Scholar
  16. Catalona WJ (1984) Prostate Cancer. Grune & Stratton, Orlando, pp 151-152Google Scholar
  17. Catalona WJ, Scott WS (1986) Carcinoma of the prostate. In: Walsh PC, Gittes RF, Perlmutter AD, Stamey TA (eds) Campbell’s urology 5, Sounders, Philadelphia, pp 1461–1534Google Scholar
  18. Chisholm GD (1974) Conservative treatment of cancer of the prostate. In: Castro JE (ed) The treatment of prostatic hypertrophy and neoplasia. MTP, Lancaster, pp 121–146Google Scholar
  19. Chisholm GD (1985) Treatment of advanced cancer of the prostate. Semin Surg Oncol 1: 38–55PubMedCrossRefGoogle Scholar
  20. Dorfman RI (1979) Biological activity of antiandrogens. Br J Dermatol 82 [Suppl 6]: 3–8Google Scholar
  21. Ellis WJ, Isaacs IT (1985) Effectiveness of complete versus partial androgen with drawal therapy for the treatment of prostatic cancer as studied in the Dunning R-3327 systems of rat prostatic adenocarcinoma. Cancer Res 45: 6041–6050PubMedGoogle Scholar
  22. Farnsworth WE (1970) The normal prostate and its endocrine control. In: Griffiths K, Pierrpoint W (eds) Some aspects of the aetiology and biochemistry of prostatic cancer. Alpha Omega Alpha, Cardiff, pp 3–15Google Scholar
  23. Faul P, Eisenberger F, Elsässer E (1985) Metastatischer Befall pelviner Lymphknoten in Abhängigkeit vom morphologischen Differenzierungsgrad und klinischen Stadium des Prostatakarzinoms. Urologe [A] 24: 326–329Google Scholar
  24. Forrest JB, Howards SS (1984) Survival following orchiectomy for stage D adeno-carcinoma of the prostate. J Surg Oncol 49: 71–74CrossRefGoogle Scholar
  25. Fossa SD, Host H, Aakvaag A (1982) Serum-Testosteronspiegel bei der Behandlung des fortgeschrittenen Prostatakarzinoms. Akt Urol 13: 273–276CrossRefGoogle Scholar
  26. Furr BJA, Hutchinson FG (1985) Biodegradable sustained release formulation of the LH RH analogue „Zoladex“ for the treatment of hormoneresponsive tumours. In EORTC Genitourinary Group Monograph 2, part A: therapeutic principles in metastatic prostatic cancer, pp 143-147Google Scholar
  27. Furr BJA, Valcaccia B, Curry B (1987) ICI 176334: A novel nonsteroidal, peripherally selectice antiandrogen. J Endocrinol 113 R7–R9PubMedCrossRefGoogle Scholar
  28. Furr BJA (1988) ICI 176334: A novel non-steroidal, peripherally selective antiandrogen. In: Management of advanced cancer of prostate and bladder. Liss, New York, pp 13–26Google Scholar
  29. Gandy H, Peterson R (1968) Measurement of testosterone and 17-KS in plasma by the double isotope dilution derivative technique. J Clin Endocrinol Metab 28: 349–353CrossRefGoogle Scholar
  30. Grayhack JT, Kozlowski JM (1980) Endocrine therapy in the management of advanced prostatic cancer; the case for early initiation of treatment. Urol Clin North Am 7: 639–643PubMedGoogle Scholar
  31. Griffiths K, Harper ME, Peeling WB (1976) Hormon studies in scientific foundation of urology, vol II. In: Williams, Chisholm GD (eds) Williams & Heinemann, London, pp 354–361Google Scholar
  32. Grossman HB (1986) Hormonal therapy of prostatic carcinoma: Is there a rationale for deloyed treatment? Urology 27: 199–204PubMedCrossRefGoogle Scholar
  33. Haapiainen R, Rannikko S, Alfthan O (1986) Comparison of primary orchiectomy with oestrogen therapy in advanced prostatic cancer Br J Urol 58: 528–533PubMedCrossRefGoogle Scholar
  34. Hofstetter AG (1986) Therapiepläne urologischer Tumoren. Urologe [B] 26 (1986) 207–209Google Scholar
  35. Hovsepian JA, Byar DP, Vacurg (1975) Carcinoma of prostate Correlation between radiologic quantitation of metastases and patient survival. Urology 6: 11–16PubMedCrossRefGoogle Scholar
  36. Huggins C, Hodges CV (1941) Studies on prostatic cancer I. The effect of castration, of estrogen and of androgen injection on the normal and on the hyperplastic prostate glands of dogs. Cancer Res 1: 293–298Google Scholar
  37. Jacobi GH (1980) Palliativtherapie des Prostatakarzinoms — Endokrinologische Grundlage, klinische Situation Prolaktin — Ein neues Prinzip. Zuckschwerdt, München 29–33Google Scholar
  38. Jacobi GH, Riedmiller H, Hohenfellner R (1981) Lokale Hochvoltbestrahlung des Prostatakarzinoms: Analyse von 214 Fällen. Verh Dtsch Ges Urol 32: 185–187Google Scholar
  39. Jacobi GH, Altwein JE (1983) Prolaktin-Inhibitoren, ein weiteres Therapieprinzip für das Karzinom der Prostata. In: Klosterhalfen H (Hrsg) Therapie des fortgeschrittenen Prostatakarzinoms. Schering, Berlin, S 41–54Google Scholar
  40. Jacobi GH, Wenderoth UK, Wallenberg H v (1988) LH RH-Analogues for palliation of advanced prostatic carcinoma. A critical review after five years of experience. In: Höffken K (Hrsg) LH RH-Agonists in oncology. Springer, Berlin Heidelberg New York Tokyo, S 72–82CrossRefGoogle Scholar
  41. Jonsson G, Olsson AM, Luttrop W (1975) Treatment of prostatic carcinoma with various types of estrogen derivatives. Vit Horm 33: 351–373CrossRefGoogle Scholar
  42. Kerle D, Williams G, Weire H (1986) Experience with an LH RH-Analogue in the management of relapsed progressive prostatic cancer. Br J Urol 56: 495–498Google Scholar
  43. Klosterhalfen H, Becker H (1987) 10-Jahres-Ergebnisse einer randomisierten Prospektivstudie beim metastasierenden Prostatakarzinom. Akt Urol 18: 234–236CrossRefGoogle Scholar
  44. Kuhn JM, Bertagna C, Billeband T (1987) Combining the antiandrogen anandron with LH RH agonist: Sequetial essays of hormones and prostate markers during a double blind study. Eur J Cancer Clin Oncol 23: 1243–1243CrossRefGoogle Scholar
  45. Labrie F, Dupont A, Belanger A (1983) New approach in the treatment of prostate cancer: complete instead of only partial withdrawal of androgens. Prostate 4: 579–594PubMedCrossRefGoogle Scholar
  46. Labrie F, Dupont A, Belanger A (1985) Long-term treatment with luteinizing hormone agonistsand maintenance of serum testosterone to castration concentrations. Br Med J 291: 369–370CrossRefGoogle Scholar
  47. Labrie F, Dupont A, Belanger A (1987) Flutamide eliminates the risk of desease flare in prostatic cancer patients treated with a LH RH agonist. J Urol 138: 804–806PubMedGoogle Scholar
  48. Labrie F, Dupont A, Gighere M (1988) Benefits of combination therapy with flutamide in patients relapsing after castration. Br J Urol 61: 341–346PubMedCrossRefGoogle Scholar
  49. Lepor H, Ross A, Walsch PC (1982) The influence of hormonal therapy on survival of men with advanced prostatic cancer. J Urol 128: 335–340PubMedGoogle Scholar
  50. Lesser B, Bruchovky N (1973) The effects of testosteron, 5-dihydrotestosterone and adenosine 3′5′monophosphate on cell proliferation and differentiation. Biochem Biophys Acta 308: 426–437PubMedGoogle Scholar
  51. Levell MJ, Siddall JK, Rowe E (1987) Relationship of testosterone, sex hormone binding globuline, and calculated free testosterone to subsequent clinical progress in patients with carcinoma of the prostate treated with bilateral orchiectomy or estrogens. Prostate 11: 17–21PubMedCrossRefGoogle Scholar
  52. Lund F, Rasmussen F (1988) Flutamide versus stilboestrol in the management of advanced prostatic cancer. A controlled prospective study. Br J Urol 61: 140–142PubMedCrossRefGoogle Scholar
  53. Manni A, Santen RJ, Boucher A (1985) Hormon stimulation and chemotherapy in advanced prostate cancer: preliminary results of prospective controlled clinical trial. Anticancer Res 5: 161–166PubMedGoogle Scholar
  54. McMahon MJ, Butler AB J, Thomas GH (1972) Morphological responses of prostatic cancer to testosterone in organ culture. Br J Urol 26: 388–394Google Scholar
  55. Mee AD, Khan O, Mashiter M (1984) High serum prolactin associated with poor prognosis in carcinoma of the prostate. Br J Urol 56: 698–701PubMedCrossRefGoogle Scholar
  56. Menon M, Walsh PC (1979) Hormonal therapy for prostatic cancer. In: Murphy GP (ed) Prostatic cancer. PSG, Littleton, pp 175–200Google Scholar
  57. Murphy GP (1977) Current status of therapy in prostatic cancer. In: Tannenbaum H (ed) Urologic pathology: the prostate. Lea & Febiger, PhiladelphiaGoogle Scholar
  58. Myers RP, Zincke R, Fleming TR (1983) Hormonal treatment at time of radical retropubic prostatectomy for stage D 1 prostate cancer. J Urol 130: 99–101PubMedGoogle Scholar
  59. Navratil H (1987) Double blind study of anandron vs placebo in stage D 2 prostate cancer patients receiving buserelin. Prog Clin Biol Res 243 A 401–410Google Scholar
  60. Neri R, Kassem N (1984) Biological and clinical properties of antiandrogens. Propr. Cancer Res Ther 31: 507–518Google Scholar
  61. Neumann F (1981) Antiandrogens: Pharmacology. In: Altwein JE, Bartsch G, Jacobi GH (Hrsg) Antihormone. Bedeutung in der Urologie. Klin Exp Urol 3: 89-115Google Scholar
  62. Nicolle P, Pontin A, Saembock L (1985) High-dose ketoconazole therapy in prostatic cancer. South Afr Med J 67: 888–889Google Scholar
  63. Paulson DF (1985) Management of metastatic prostatic cancer. Urology 25 [Suppl] 49–52PubMedCrossRefGoogle Scholar
  64. Pavone-Macaluso M, de Vogt HJ, Viggiano G (1986) Comparison of diethylstilbestrol, cyproterone acetateand medroxy-progesterone acetate in the treatment of advanced prostatic cancer: Final analepsis of a randomized phase III trial of the EORTC Urological group. J Urol 136: 624–631PubMedGoogle Scholar
  65. Pollen JJ (1983) Endocrine treatment of prostatic cancer. Urology 21: 555–558PubMedCrossRefGoogle Scholar
  66. Raynaud JP, Bonne C, Moguilewsky M (1984) The pure antiandrogen RU 23908 (Anandron), a candidate of choice for the combined antihormonal treatment of prostatic cancer: a Review. Prostate 5: 299–311PubMedCrossRefGoogle Scholar
  67. Robinson MRG (1983) Carcinoma of the prostate: Adrenal inhibitors. In: Pavone-Macaluso M, Smith PH (eds) Cancer of the prostate and kidney. Plenum, New York, pp 349–354.Google Scholar
  68. Rohlf PL, Flocks RH (1969) Stilphostrol therapy in 100 cases of prostatic carcinoma. J Iowa Med Soc 59: 1096–1101PubMedGoogle Scholar
  69. Sandberg AA (1983) Metabolic aspects and actions unique to estracyt. Semin Oncol 10 [Suppl]: 3–15PubMedGoogle Scholar
  70. Sanford EJ, Paulson DF, Robner TJ (1977) The effects of castration on adrenal testosterone secretion in men with prostatic carcinoma. J Urol 118: 1019–1021PubMedGoogle Scholar
  71. Santen RJ, Bardin CW (1973) Episodic luteinizing hormone secretion in man. Pulse analepsis, clinical interpretation, physio-logical mechanisms. J Clin Invest 52: 2617–2633PubMedCrossRefGoogle Scholar
  72. Schaison G, Brailly S, Vuagnat P (1984) Absence of a direct inhibitory effect of the GnRH agonist D-Ser (TBU)6, des-Gly-NH2 10 GnRH ethylamide (Buserelin) on testicular steroid genesis in man. J Clin Endocrinol 58: 885–888CrossRefGoogle Scholar
  73. Schally AV, Redding TW, Comaru-Schally AM (1983) Inhibition of prostate tumors by agonistic and antagonistic analogs of LH RH. Prostata 4: 545–552CrossRefGoogle Scholar
  74. Shearer RJ, Hendry WF, Sommerville IF (1973) Plasma testosterone; An accurate monitor of hormone treatment in prostatic cancer. Br J Urol 45: 668–677PubMedCrossRefGoogle Scholar
  75. Sinha AA, Blackard CE, Seal UA (1977) A critical analysis of tumor morphology and hormone treatments in the untreated and estrogen-treated responsive and refactory human prostatic carcinoma. Cancer 40: 2836–2850PubMedCrossRefGoogle Scholar
  76. Skipper HE (1971) Kinetics of mammary tumor all growth and implications for therapy. Cancer 28: 1479–1499PubMedCrossRefGoogle Scholar
  77. Smith JA (1987) New Methods of endocrine management of prostatic cancer. J Urol 137: 1–10PubMedGoogle Scholar
  78. Stege R, Carström K, Collste C (1987) Single drug polyestradiol phosphate (REP) therapy in prostatic cancer (CAP). Eur J Cancer Clin Oncol 23: 1249CrossRefGoogle Scholar
  79. Stein BW, Smith JA (1985) DES lead-in to use of luteinizing hormone releasing hormone analogs in treatment of metastatic carcinoma of the prostate. Urology 25: 350–353PubMedCrossRefGoogle Scholar
  80. Stone AR, Hargreave TB, Chisholm GD (1980) The diagnosis of estrogen escape and the role of secondary orchiectomy in prostatic cancer. Br J Urol 52: 535–538PubMedCrossRefGoogle Scholar
  81. Straube W, Braun JS (1974) Zur Orchiektomie und Oestrogentherapie des Prostatakarzinoms. Urologe [A] 13: 198–201Google Scholar
  82. Sufrin G, Coffey DS (1973) New Model for studying the effect of drugs on prostatic growth. I. Antiandrogenes and DNA synthesis. Invest Urol II: 45–54Google Scholar
  83. Trachtenberg J (1984) Ketoconazole therapy in advanced prostatic cancer. J Urol 132: 61–63PubMedGoogle Scholar
  84. Walsh PC, Korenman SG (1971) Mechanism of androgenic action: effect of specific intracellular inhibitors. J Urol 105: 850–857PubMedGoogle Scholar
  85. Walsh PC (1975) Physiologic basis for hormonal therapy in carcinoma of the prostate. Urol Clin North Am 2: 125–140PubMedGoogle Scholar
  86. Wander HE (1987) Zur Hormontherapie maligner Erkrankungen. Die gelben Hefte 27: 115–122Google Scholar
  87. Wenderoth UK, Jacobi GH (1985) Langzeitergebnisse mit dem GnRH Analogon Buserelin (Suprefact) bei der Behandlung des fortgeschrittenen Prostatkarzinoms seit 1981. Akt Urol 16: 58–63CrossRefGoogle Scholar
  88. Williams G, Kerle DJ, Ware H (1986) Objective responses to ketoconazole therapy in patients with relapsed progressive prostatic cancer. Br J Urol 58: 45–51PubMedCrossRefGoogle Scholar
  89. Witorsch RJ, Smith JP (1977) Evidence for androgen dependent intracellular binding of prolactin in rat ventral prostate gland. Endocrinology 101: 929–938PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1991

Authors and Affiliations

  • J. E. Altwein
    • 1
  • P. Faul
    • 2
  1. 1.Androcur®, ScheringUSA
  2. 2.Fugerel®, Essex-PharmaUSA

Personalised recommendations